STOCK TITAN
  1. Home
  2. News
  3. RMTI

Rockwell Medical Inc - RMTI STOCK NEWS

Welcome to our dedicated news page for Rockwell Medical (Ticker: RMTI), a resource for investors and traders seeking the latest updates and insights on Rockwell Medical.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Rockwell Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Rockwell Medical's position in the market.

News
Rockwell Medical Continues to Expand its Distribution Capabilities in Western United States
Rhea-AI Summary
Rockwell Medical, Inc. (Nasdaq: RMTI) has entered into a new direct supply agreement with one of the largest health systems in the Mountain West region of the United States. The agreement includes supplying liquid and dry acid and bicarbonate hemodialysis concentrates, cleaning agents, hemodialysis concentrates mixers, and other products. This move aims to enhance distribution capabilities and support dialysis providers in the region, ensuring patients with chronic kidney disease and end-stage renal disease receive high-quality care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
none
-
News
Rockwell Medical to Release First Quarter 2024 Results on Tuesday, May 14, 2024
Rhea-AI Summary
Rockwell Medical, Inc. (RMTI) will release its first quarter 2024 financial and operational results on May 14, 2024. The Company develops, manufactures, and distributes hemodialysis products globally. A live conference call and webcast will follow the press release.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.61%
Tags
earnings
-
News
Rockwell Medical Expands Global Distribution in the Dominican Republic and Bermuda
Rhea-AI Summary
Rockwell Medical (RMTI) announces new distribution agreements with BioNuclear and AMI, expected to generate $1 million in annual revenues. The agreements aim to expand the global reach of hemodialysis products, reinforcing the company's position in the market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.68%
Tags
none
News
Rockwell Medical Named 'Great Place to Work' for Second Year in a Row
Rhea-AI Summary
Rockwell Medical, Inc. (RMTI) has been certified as a Great Place to Work® for the second consecutive year, showcasing employee satisfaction and positive work culture.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
none
-
News
Rockwell Medical Achieves Profitability on an Adjusted EBITDA Basis in the Fourth Quarter 2023 and Record Net Sales, Gross Profit and Gross Margin for the Full-Year 2023
Rhea-AI Summary
Rockwell Medical, Inc. (RMTI) reports record net sales and gross profit for the second consecutive year in 2023, with net sales reaching $83.6 million and gross profit hitting $8.7 million. Achieving profitability on an adjusted EBITDA basis in Q4 2023, the company issues 2024 guidance projecting net product sales between $84 million and $88 million, gross margin between 14% and 16%, and profitability on an adjusted EBITDA basis for the full year 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.88%
Tags
earnings
-
News
Rockwell Medical to Release Fourth Quarter and Full-Year 2023 Results on Thursday, March 21, 2024
Rhea-AI Summary
Rockwell Medical, Inc. (RMTI) will release its financial and operational results for the fourth quarter and full-year ended December 31, 2023 on Thursday, March 21, 2024. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET. The conference call will include a discussion of fourth quarter and full-year 2023 operational and financial results followed by Q&A.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.6%
Tags
earnings
News
Rockwell Medical Amends Loan and Security Agreement with Innovatus Life Sciences Lending Fund
Rhea-AI Summary
Rockwell Medical, Inc. (Nasdaq: RMTI) announced the amendment of its loan and security agreement with Innovatus Life Sciences Lending Fund I, LP, deferring principal payments of $8.0 million up to three years. The amendment reduces the Company's need for additional operating capital and enhances its cash balance. The Company also provided preliminary projected fourth quarter and full-year 2023 financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.71%
Tags
none
-
News
Rockwell Medical Announces Third Quarter 2023 Results
Rhea-AI Summary
RMTI - Rockwell Medical, Inc. Announces Record Third Quarter 2023 Financial and Operational Results, Expects Profitability in Fourth Quarter. Net sales for the third quarter of 2023 were $23.8 million, including concentrates product sales of $21.6 million, the highest sales generated to-date for the Company. Gross profit for the third quarter of 2023 increased 183% over the same period in 2022. Rockwell Medical reiterates projected 2023 net sales to be between $82.0 million and $86.0 million, an increase of 17% to 18% year-over-year, and projected 2023 gross profit to between $8.0 million and $10.0 million, an increase of 95% to 144% year-over-year. The Company expects to achieve profitability on an adjusted EBITDA basis in the fourth quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
earnings
-
News
Rockwell Medical Names Jesse Neri as Senior Vice President, Finance
Rhea-AI Summary
Rockwell Medical announces the appointment of Jesse Neri as Senior Vice President, Finance
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.28%
Tags
none
News
Rockwell Medical Appoints Joan Lau, Ph.D. to the Company's Board of Directors
Rhea-AI Summary
Rockwell Medical appoints Joan Lau, Ph.D. to its board of directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
management
Stock RMTI logo
Rockwell Medical Inc

Nasdaq:RMTI

RMTI Rankings

#4797 Ranked by Market Cap
#245 Ranked by Stock Gains
N/A Ranked by Dividends

RMTI Stock Data

46.94M
25.22M
3.01%
17.46%
2.3%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Wixom

About RMTI

rockwell medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (esrd) and chronic kidney disease (ckd) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis. rockwell’s new innovative therapy triferic is the only fda approved drug indicated to replace iron and maintain hemoglobin in hemodialysis patients suffering from anemia. via dialysate during each dialysis treatment, triferic replaces the 5-7 mg iron loss that occurs in all patients, maintaining their iron balance. unlike iv iron products, triferic binds iron immediately and completely to transferrin (carrier of iron in the body) upon entering the blood and is then transported directly to the bone marrow to be incorporated into hemoglobin, with no increase in ferritin (stored iron and inflammation) and no anaphylaxis, addressing a significant unmet need in overcoming functional iron deficiency (fid) in esrd patients. visit www